Market revenue in 2021 | USD 49.1 million |
Market revenue in 2030 | USD 317.9 million |
Growth rate | 23.1% (CAGR from 2021 to 2030) |
Largest segment | Serum biomarkers |
Fastest growing segment | Hepatic Fibrosis Biomarkers |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers |
Key market players worldwide | Genfit SA, Siemens AG, Quest Diagnostics Inc, AstraZeneca PLC, Meridian Bioscience, Labcorp Holdings Inc, Pfizer Inc, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-alcoholic steatohepatitis biomarkers market will help companies and investors design strategic landscapes.
Serum biomarkers was the largest segment with a revenue share of 32.59% in 2021. Horizon Databook has segmented the UK non-alcoholic steatohepatitis biomarkers market based on serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers covering the revenue growth of each sub-segment from 2018 to 2030.
The UK is projected to witness significant growth in Europe after Germany. In the UK, all medical needs are completely covered by NHS and the National Institute of Health and Care Research (NIHR) provides an integrated health research system.
A well-developed healthcare infrastructure enables doctors to use biomarkers. An increase in the number of initiatives being undertaken by private and public organizations to fund R&D for biomarkers is anticipated to propel market growth.
For instance, the University of Edinburgh granted research funding of USD 2.61 million under “HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies” and Liver Multi scan with MRI— replacing liver biopsy Furthermore, R&D of potential biomarkers may propel the growth of the NASH biomarkers market.
Horizon Databook provides a detailed overview of country-level data and insights on the UK non-alcoholic steatohepatitis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into UK non-alcoholic steatohepatitis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account